Literature DB >> 24796386

Accessory vein obliteration criteria for immature fistulae: a modest proposal for an old paradigm.

Naveed Ul Haq1, Mamdouh Albaqumi.   

Abstract

Venous stenosis and/or presence of accessory vein (av) are the two most common causes of early fistula failure. While treatment of stenosis is better defined, there are no clear criteria for obliteration of the av. Often, interventionalists rely on visual assessment of flow through the av and its diameter (significant if > 1/3 of the main fistula diameter) for intervention. The purpose of this study was to establish objective criteria for the management of av. Various computational fluid dynamics simulations were performed to analyze blood flow in the arteriovenous fistula (AVF). av of different diameters and angles was then added at various locations in the AVF and comparison of simulation results was undertaken. The computational model revealed that when the av was 33% of the diameter of the AVF, flow in av was only 7%. When diameter of the av was increased to 50% and 66% of the diameter of the AVF, flow through the av was 10% and 31% of the flow in main AVF, respectively. Location or angle of take-off of av did not alter flow. This report provides objective information regarding criteria for av obliteration. It needs to be further validated in randomized clinical trials.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24796386     DOI: 10.1111/sdi.12239

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  2 in total

1.  Venous outflow banding for maturation of a percutaneous arteriovenous fistula.

Authors:  Maria Barahona; Britt Tonnessen; Jonathan Cardella; Anushree Shirali; Juan Carlos Perez-Lozada; Cassius Iyad Ochoa Chaar
Journal:  J Vasc Surg Cases Innov Tech       Date:  2022-01-03

2.  Endovascular management in immature arteriovenous fistula for hemodialysis.

Authors:  Shin Jae Lee; Gyeong Sik Jeon; Byungmo Lee; Gun Lee; Jung Jun Lee
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.